05.31.07
Posted in Uncategorized at 9:40 pm by Yahoo! Health: Cancer News
The percentage of American adults who got sunburned increased from 31.8 percent to 33.7 percent from 1999 and 2004, a sign that many people aren't using proper sun protection, a new study found.
Permalink
Posted in Uncategorized at 9:40 pm by Yahoo! Health: Breast Cancer News
A sophisticated radiation therapy system safely allows the delivery of a higher daily dose for breast cancer patients and shortens the treatment time for women from six or seven weeks to just four, researchers say.
Permalink
Posted in Uncategorized at 5:55 pm by Yahoo! Health: Cancer News
The US Food and Drug Administration has approved the drug temsirolimus for advanced renal cell carcinoma, a form of kidney cancer. The announcement coincides with the publication this week of a study showing the drug helps people with this late-stage disease live longer.
Permalink
Posted in Uncategorized at 1:00 pm by Cancer / Oncology News From Medical News Today
H. Lee Moffitt Cancer Center & Research Institute's Dr. Lodovico Balducci will receive the B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology at the 6th Annual American Society of Clinical Oncology (ASCO) Conference June 1-5 in Chicago. Balducci is the Program Leader of Moffitt's Senior Adult Oncology Program and Chief of the Division of Geriatric Oncology. "I feel proud to have my name associated with B. J. Kennedy," said Balducci. [click link for full article]
Permalink
Posted in Uncategorized at 11:00 am by Lung Cancer News From Medical News Today
Coinciding with today being World No Tobacco Day, the World Health Organization (WHO) is urging all countries to bring in a 100 per cent ban on smoking in indoor public places and workplaces and has released its new policy recommendations on protection from exposure to second-hand tobacco smoke."The evidence is clear, there is no safe level of exposure to second-hand tobacco smoke," said WHO Director-General Dr Margaret Chan in a prepared statement earlier this week. [click link for full article]
Permalink
Posted in Uncategorized at 11:00 am by Cancer / Oncology News From Medical News Today
Scientists showed that curcumin, the main ingredient of the Indian herb turmeric, restores key immune cells that fight off cancer.The immune system of patients with advanced cancer is significantly weakened, mostly because the main cells that fight off tumors either cannot proliferate anymore or have died off. Curcumin was previously shown to have anti-tumor activity but its effects on the immune system were unknown - until now. [click link for full article]
Permalink
Posted in Uncategorized at 7:30 am by American Cancer Society :: News and Features
The experimental drug temsirolimus helps people with advanced kidney cancer live longer than standard treatment, a new study says.
Permalink
Posted in Uncategorized at 7:00 am by Breast Cancer News From Medical News Today
Researchers at the Abramson Family Cancer Research Institute of the University of Pennsylvania and the Dana-Farber Cancer Institute describe in Science a new candidate breast-cancer susceptibility gene. The Rap80 gene is required for the normal DNA-repair function of the well-known breast cancer gene BRCA1.Cancer-causing mutations in the BRCA1 protein fail to bind to the Rap80 protein. Consequently BRCA1 is unable to identify DNA damage sites in the genome. [click link for full article]
Permalink
Posted in Uncategorized at 1:00 am by Cancer / Oncology News From Medical News Today
Celldex Therapeutics announced today that clinical data from studies with its two lead product candidates, CDX-110 and CDX-1307, will be presented during poster sessions at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). The ASCO meeting is being held at McCormick Place in Chicago, IL from Friday, June 1 through Tuesday, June 5. [click link for full article]
Permalink
Posted in Uncategorized at 1:00 am by Cancer / Oncology News From Medical News Today
Mersana Therapeutics, a cancer therapeutics company, announced today that it has initiated a Phase I open-label, dose-escalation trial of its lead product candidate, XMT-1001, in patients with solid tumors. XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. The primary objectives of the study are to determine the safety, tolerability and pharmacokinetic profile of XMT-1001. [click link for full article]
Permalink
« Previous entries
